A Phase 3 interventional study of Pramipexol Extended Release and Pramipexol Immediate Release in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 76 sites in 14 countries. Open to participants aged 32 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 5th largest by enrollment, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 9th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 32 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 517 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2007, is one of 10 in phase 3, and was the 10th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined), safety, and tolerability of pramipexole ER, in daily doses from 0.375 milligram to 4.5 milligram once a day, in comparison to placebo, in Levodopa combined with a Dopa-Decarboxylase-inhibitor treated Parkinson patients with advanced Parkinsons Disease and motor fluctuations.
In addition, a numerical comparison of the efficacy of pramipexole extended release versus pramipexole immediate release will be done.
The efficacy of pramipexole immediate release will also be compared to placebo, for assay sensitivity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pramipexol Extended Release
Drug: Pramipexol Immediate Release
Drug: Placebo
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18
UPDRS II+III total score on Full Analysis Set (FAS)with LOCF (Last observation carried forward), week 18 - baseline, UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
Time frame: baseline and week 18
Change From Baseline in Percentage Off-time at Week 18
Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
Time frame: baseline and week 18
Change From Baseline in Percentage On-time Without Dyskinesia at Week 18
Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and week 18
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18
Percentage on-time with non-troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and week 18
Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18
Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
Time frame: baseline and week 18
Clinical Global Impression - Global Improvement (CGI-I) Responder
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)
Time frame: after 18 weeks of treatment
Response in Patient Global Impression (PGI-I)
PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring 1 or 2 (at least much better)
Time frame: after 18 weeks of treatment
Change From Baseline in UPDRS I Score After 18 Weeks
UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood
Time frame: baseline and 18 weeks
Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period
UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities.
Time frame: baseline and 18 weeks
Change From Baseline in UPDRS III Score After 18 Weeks
UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms
Time frame: baseline and 18 weeks
Change From Baseline in UPDRS IV Score After 18 Weeks
UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy
Time frame: baseline and 18 weeks
Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks
ranging from 0 (best case) to 63 (worst case)
Time frame: baseline and 18 weeks
Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks
ranging from 0 (worst case) to 150 (best case)
Time frame: baseline and 18 weeks
Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks
Ranging from 0 (best case) to 156 (worst case)
Time frame: baseline and 18 weeks
Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks
ranging from 0 (worst case) to 100 (best case)
Time frame: baseline and 18 weeks
Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18
Likert scale is a method used for the measurement of pain. The patients were asked to rate their pain related to PD by ticking the number that best described their pain on the average in the previous week, from zero for "no pain" to ten for "unbearable pain".
Time frame: baseline and week 18
Clinically Significant Abnormalities: Clinical Laboratory Evaluations (Biochemistry and Haematology)
Time frame: baseline and week 18
| Milestone | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Started | 165 | 175 | 178 |
| Completed | 145 | 163 | 157 |
| Not completed | 20 | 12 | 21 |
| Withdrew: Adverse event | 8 | 8 | 7 |
| Withdrew: Lack of efficacy | 2 | 0 | 3 |
| Withdrew: Protocol violation | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 | 6 |
| Withdrew: Patient did not meet inclusion criteria | 1 | 0 | 1 |
| Withdrew: Not treated | 1 | 0 | 0 |
UPDRS II+III total score on Full Analysis Set (FAS)with LOCF (Last observation carried forward), week 18 - baseline, UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms
| Percentage of change from baseline | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18 | -11.0 ± 1.0 | -12.8 ± 0.9 | -6.1 ± 0.9 |
Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
| Percentage of off-time | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage Off-time at Week 18 | -13.3 ± 1.4 | -15.9 ± 1.3 | -8.8 ± 1.3 |
Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time without dyskinesia | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage On-time Without Dyskinesia at Week 18 | 11.9 ± 1.7 | 12.6 ± 1.7 | 8.9 ± 1.6 |
Percentage on-time with non-troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18 | 1.9 ± 1.2 | 3.9 ± 1.2 | 1.0 ± 1.2 |
Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.
| Percentage of on-time | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18 | -0.8 ± 0.5 | -0.8 ± 0.5 | -1.0 ± 0.5 |
CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)
| Participants | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Responder | 78 | 88 | 56 |
| Non-Responder | 82 | 81 | 115 |
PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring 1 or 2 (at least much better)
| Participants | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Responder | 60 | 76 | 47 |
| Non-Responder | 101 | 96 | 127 |
UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in UPDRS I Score After 18 Weeks | 0 (-1.0 to 0.0) | 0 (-1.0 to 0.0) | 0 (-1.0 to 0.0) |
UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities.
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period | -2.7 ± 0.3 | -3.6 ± 0.3 | -1.9 ± 0.3 |
UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in UPDRS III Score After 18 Weeks | -8.3 ± 0.7 | -9.2 ± 0.7 | -4.3 ± 0.7 |
UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in UPDRS IV Score After 18 Weeks | -0.8 ± 0.2 | -0.9 ± 0.2 | -0.6 ± 0.2 |
ranging from 0 (best case) to 63 (worst case)
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks | -3.2 ± 0.5 | -4.0 ± 0.5 | -2.8 ± 0.5 |
ranging from 0 (worst case) to 150 (best case)
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks | 8.1 ± 1.8 | 8.9 ± 1.7 | 4.9 ± 1.7 |
Ranging from 0 (best case) to 156 (worst case)
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks | -9.1 ± 1.9 | -13.1 ± 1.8 | -6.2 ± 1.8 |
ranging from 0 (worst case) to 100 (best case)
| Units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks | 5.8 ± 1.4 | 7.6 ± 1.3 | 4.3 ± 1.3 |
Likert scale is a method used for the measurement of pain. The patients were asked to rate their pain related to PD by ticking the number that best described their pain on the average in the previous week, from zero for "no pain" to ten for "unbearable pain".
| units on a scale | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18 | -0.4 ± 0.2 | -1.0 ± 0.2 | -0.3 ± 0.2 |
| participants | Pramipexole ER | Pramipexole IR | Placebo |
|---|---|---|---|
| Haematocrit - decrease | 2 (26.8 to 43.5) | 3 (32.4 to 48.8) | 1 (13.5 to 26.9) |
| Haemoglobin - decrease | 2 | 5 | 3 |
| Red blood cell ct - decrease | 1 | 0 | 1 |
| Eosinophils - Increase | 3 | 2 | 1 |
| Neut.,poly. (segs),absol. - decrease | 0 | 1 | 0 |
| Sodium - decrease | 0 | 2 | 0 |
| GGT - increase | 1 | 0 | 1 |
| Glucose - decrease | 1 | 0 | 1 |
| Glucose - increase | 0 | 2 | 1 |
| Triglyceride - increase | 2 | 3 | 5 |
| Weight - decrease | 0 | 3 | 1 |
| Blood pressure - increase | 1 | 2 | 0 |
| Blood pressure - decrease | 0 | 0 | 1 |
Collected over From the first dose of trial medication onwards up to the end of the trial (up to 34 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 15/178 (8.4%) | 74/178 (41.6%) |
| Pramipexole ER | — | 8/164 (4.9%) | 73/164 (44.5%) |
| Pramipexole IR | — | 11/175 (6.3%) | 90/175 (51.4%) |
| Event | Placebo | Pramipexole ER | Pramipexole IR |
|---|---|---|---|
| Hallucination, visualPsychiatric disorders | 0/178 | 2/164 | 0/175 |
| InsomniaPsychiatric disorders | 0/178 | 0/164 | 2/175 |
| FallInjury, poisoning and procedural complications | 0/178 | 0/164 | 2/175 |
| BronchitisInfections and infestations | 0/178 | 1/164 | 0/175 |
| DelusionPsychiatric disorders | 0/178 | 1/164 | 1/175 |
| Depressed level of consciousnessNervous system disorders | 0/178 | 1/164 | 0/175 |
| Disturbance in attentionNervous system disorders | 0/178 | 1/164 | 0/175 |
| PresyncopeNervous system disorders | 0/178 | 1/164 | 0/175 |
| HypotensionVascular disorders | 0/178 | 1/164 | 0/175 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/178 | 1/164 | 0/175 |
| Event | Placebo | Pramipexole ER | Pramipexole IR |
|---|---|---|---|
| DyskinesiaNervous system disorders | 16/178 | 28/164 | 34/175 |
| SomnolenceNervous system disorders | 29/178 | 24/164 | 30/175 |
| NauseaGastrointestinal disorders | 19/178 | 18/164 | 20/175 |
| DizzinessNervous system disorders | 9/178 | 9/164 | 19/175 |
| HeadacheNervous system disorders | 5/178 | 14/164 | 9/175 |
| NasopharyngitisInfections and infestations | 12/178 | 3/164 | 7/175 |
| ConstipationGastrointestinal disorders | 9/178 | 11/164 | 10/175 |
| HallucinationPsychiatric disorders | 2/178 | 9/164 | 10/175 |
| VomitingGastrointestinal disorders | 5/178 | 2/164 | 10/175 |
| AnorexiaMetabolism and nutrition disorders | 4/178 | 9/164 | 2/175 |
| Age, Continuous(years) | Pramipexole ER | Pramipexole IR | Placebo | Total |
|---|---|---|---|---|
| Mean | 61.6 ± 9.7 | 62.0 ± 10.3 | 60.9 ± 9.7 | 61.5 ± 9.9 |
| Sex: Female, Male(Participants) | Pramipexole ER | Pramipexole IR | Placebo | Total |
|---|---|---|---|---|
| Female | 72 | 77 | 84 | 233 |
| Male | 92 | 98 | 94 | 284 |
The record gives a start of Apr 2007 and a primary completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole